Efficacy News and Research

RSS

Nerve cells from horse stem cells may pave way for cell therapies, say researchers

Horses suffering from neurological conditions similar to those that affect humans could be helped by a breakthrough from stem cell scientists.

5 Mar 2014

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.

4 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

Procellera technology enhances cell migration in in-vitro laboratory testing

Procellera – the world's first wireless microcurrent generating dressing that produces electrical fields through its matrix of microcell batteries – was found to significantly enhance cell migration in in-vitro laboratory testing, according to groundbreaking research led by The Ohio State University Wexner Medical Center Professor Chandan K. Sen. Professor Sen is also the Director of the Comprehensive Wound Center at Ohio State.

4 Mar 2014

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.

4 Mar 2014

New AskRx version 1.0 enables patients to ask health and medication questions

RxWiki, Inc. announced today the launch of AskRx version 1.0, enabling patients to ask Digital Pharmacists™ health and medication questions.

4 Mar 2014

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

4 Mar 2014

Medical student receives award for finding out drugs to treat peripheral vascular disease

Working at a Saint Louis University laboratory, second-year medical student Weston Gordon performed several studies investigating two novel drug therapies that may be useful in the treatment of peripheral vascular disease in patients with Type 2 diabetes.

4 Mar 2014

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.

4 Mar 2014

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Using a yeast model of Alzheimer's disease (AD), Whitehead Institute researchers have identified a drug that reduces levels of the toxic protein fragment amyloid-β (Aβ) and prevents at least some of the cellular damage caused when Aβ accumulates in the brains of AD patients.

4 Mar 2014

Noninvasive imaging with MRI of carotid artery plaque accurately predicts future cardiovascular events

Noninvasive imaging of carotid artery plaque with MRI can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular disease, according to a new study published online in the journal Radiology.

4 Mar 2014

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.

4 Mar 2014

Study: Self-administration of flu vaccines with microneedle patches may one day be feasible

The annual ritual of visiting a doctor's office or health clinic to receive a flu shot may soon be outdated, thanks to the findings of a new study published in the journal Vaccine.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

New article explores risks associated with using herbal cannabis for rheumatic conditions

Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

3 Mar 2014

Efficacy News and Research

Nerve cells from horse stem cells may pave way for cell therapies, say researchers

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Procellera technology enhances cell migration in in-vitro laboratory testing

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

New AskRx version 1.0 enables patients to ask health and medication questions

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Medical student receives award for finding out drugs to treat peripheral vascular disease

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Noninvasive imaging with MRI of carotid artery plaque accurately predicts future cardiovascular events

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

Study: Self-administration of flu vaccines with microneedle patches may one day be feasible

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

New article explores risks associated with using herbal cannabis for rheumatic conditions

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News